Will Imatinib Compromise Reproductive Capacity?

Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia-positive leukemias and selected other cancers, leading to a steady rise in the prevalence of patients using such therapy. Because failure of therapy would require conven...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zamah, Alberuni M., Mauro, Michael J., Druker, Brian J., Oktay, Kutluk, Egorin, Merrill J., Cedars, Marcelle I., Rosen, Mitchell P.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2011
Assuntos:
Leukemias
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228060/
https://ncbi.nlm.nih.gov/pubmed/21948652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0137
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados